REFLECTION: A Clinical Practice Learning Program for Galleri®
REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program for Galleri®
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: GRAIL Customer Service
- Phone Number: 833-694-2553
- Email: customerservice@grail.com
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- Vincere Cancer Center
-
-
California
-
Burbank, California, United States, 91505
- Providence
-
Fullerton, California, United States, 92835
- Providence, St. Jude
-
Mission Viejo, California, United States, 92691
- Providence, Mission
-
Orange, California, United States, 92868
- Providence, Orange County
-
-
Florida
-
Miami, Florida, United States, 33125
- VA Miami Health Care System
-
Tampa, Florida, United States, 33612
- James A. Haley Veterans Hospital (VA Tampa)
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70119
- Southeast Louisiana Veterans Health Care System (SLVHCS) (VA New Orleans)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111-1750
- Boston VA Research Institute (VA Boston)
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15240
- VA Pittsburgh Healthcare System
-
Wilkes-Barre, Pennsylvania, United States, 18711
- VA Wilkes Barre Medical Center
-
-
South Carolina
-
Lancaster, South Carolina, United States, 29720
- Carolina Blood and Cancer Care Associate
-
Rock Hill, South Carolina, United States, 29732
- Carolina Blood and Cancer Care Associates
-
-
Utah
-
Salt Lake City, Utah, United States, 84148
- VA Salt Lake City Health Care System (VASLCHCS)
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26501
- WVU University Town Centre Family Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
- Participant has the ability to understand and the willingness to sign a written informed consent form (ICF);
- Participant is at least 22 years old at the time of consent;
- A provider or their designee has ordered the Galleri® test; and
- Participant has the ability to comprehend the participant questionnaires.
Exclusion Criteria:
- There are no exclusions
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients who received the Galleri® test.
|
Multi-cancer early detection (MCED) test
Standard of care cancer screening
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To describe signal detection and cancer detection within and across sites among participants who opt to receive Galleri® in a real world setting.
Time Frame: Up to 12 Months
|
Up to 12 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Galleri®: To assess the feasibility and acceptability of Galleri® from the perspective of participants and patient-reported outcomes (PROs) in a real-world setting.
Time Frame: Up to 12 Months
|
Up to 12 Months
|
|
HCRU: To assess healthcare resource utilization (HCRU) associated with cancer diagnostic workups for participants with signal detected Galleri® test results.
Time Frame: Up to 12 Months
|
Up to 12 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GRAIL-MA-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.